Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.

Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S, Alam M, Putri FA, Bastard M, Docteur W, Gottlieb G, Hewison C, Islam S, Khachatryan N, Kotrikadze T, Khan U, Kumsa A, Lecca L, Tassew YM, Melikyan N, Naing YY, Oyewusi L, Rich M, Wanjala S, Yedilbayev A, Huerga H, Mitnick CD; endTB Study Group.

Clin Infect Dis. 2019 Nov 2. pii: ciz1084. doi: 10.1093/cid/ciz1084. [Epub ahead of print]

PMID:
31676905
2.

Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study.

Becerra MC, Huang CC, Lecca L, Bayona J, Contreras C, Calderon R, Yataco R, Galea J, Zhang Z, Atwood S, Cohen T, Mitnick CD, Farmer P, Murray M.

BMJ. 2019 Oct 24;367:l5894. doi: 10.1136/bmj.l5894.

3.

Disrupting a cycle of mistrust: A constructivist grounded theory study on patient-provider trust in TB care.

Law S, Daftary A, Mitnick CD, Dheda K, Menzies D.

Soc Sci Med. 2019 Nov;240:112578. doi: 10.1016/j.socscimed.2019.112578. Epub 2019 Sep 26.

PMID:
31585376
4.

Causal inference in tuberculosis treatment studies: bias considerations and data needs.

Franke MF, Rodriguez CA, Mitnick CD.

Int J Tuberc Lung Dis. 2019 Aug 1;23(8):960-961. doi: 10.5588/ijtld.19.0037. No abstract available.

PMID:
31533889
5.

Value of observational data for multidrug-resistant tuberculosis.

Rodriguez CA, Mitnick CD, Franke MF.

Lancet Infect Dis. 2019 Sep;19(9):930-931. doi: 10.1016/S1473-3099(19)30424-4. No abstract available.

PMID:
31478514
6.

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.

Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, Varaine F, Bastard M, Rich M, Franke MF, Atwood S, Khan PY, Seung KJ.

BMC Infect Dis. 2019 Aug 20;19(1):733. doi: 10.1186/s12879-019-4378-4.

7.

Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study.

Rodriguez CA, Brooks MB, Guglielmetti L, Hewison C, Jachym MF, Lessem E, Varaine F, Mitnick CD.

Public Health Action. 2019 Mar 21;9(1):32-41. doi: 10.5588/pha.18.0078.

8.

Tuberculosis active case-finding: more than just finding cases.

Mitnick CD, Yuen CM.

Lancet Infect Dis. 2019 May;19(5):456-457. doi: 10.1016/S1473-3099(19)30065-9. Epub 2019 Mar 22. No abstract available.

9.

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.

Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ.

PLoS Med. 2019 Mar 22;16(3):e1002767. doi: 10.1371/journal.pmed.1002767. eCollection 2019 Mar. Review.

10.

Asthma and atopy prevalence are not reduced among former tuberculosis patients compared with controls in Lima, Peru.

Byrne AL, Marais BJ, Mitnick CD, Garden FL, Lecca L, Contreras C, Yauri Y, Garcia F, Marks GB.

BMC Pulm Med. 2019 Feb 13;19(1):40. doi: 10.1186/s12890-019-0804-z.

11.

Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.

Velásquez GE, Brooks MB, Coit JM, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Lecca L, Davies GR, Mitnick CD.

Am J Respir Crit Care Med. 2019 May 1;199(9):1167-1168. doi: 10.1164/rccm.201812-2281LE. No abstract available.

12.

Use of predicted vital status to improve survival analysis of multidrug-resistant tuberculosis cohorts.

Brooks MB, Keshavjee S, Gelmanova I, Zemlyanaya NA, Mitnick CD, Manjourides J.

BMC Med Res Methodol. 2018 Dec 11;18(1):166. doi: 10.1186/s12874-018-0637-0.

13.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

14.

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR Jr.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00770-18. doi: 10.1128/AAC.00770-18. Print 2018 Oct.

15.

Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.

Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):657-666. doi: 10.1164/rccm.201712-2524OC.

16.

Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis.

Velásquez GE, Davies GR, Mitnick CD.

Int J Tuberc Lung Dis. 2018 May 1;22(5):473-474. doi: 10.5588/ijtld.18.0210. No abstract available.

17.

Time to revise WHO-recommended definitions of MDR-TB treatment outcomes.

Lange C, van Leth F, Mitnick CD, Dheda K, Günther G.

Lancet Respir Med. 2018 Apr;6(4):246-248. doi: 10.1016/S2213-2600(18)30104-8. No abstract available.

PMID:
29595505
18.

Feasibility and yield of screening for non-communicable diseases among treated tuberculosis patients in Peru.

Byrne AL, Marais BJ, Mitnick CD, Garden FL, Lecca L, Contreras C, Yauri Y, Garcia F, Marks GB.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):86-92. doi: 10.5588/ijtld.17.0381.

PMID:
29297431
19.

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr.

Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.

20.
21.

Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".

Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Garavito ES, Vasquez DV, Mitnick CD, Davies G.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01524-17. doi: 10.1128/AAC.01524-17. Print 2017 Sep. No abstract available.

22.

Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.

Calderón RI, Velásquez GE, Becerra MC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Kritski AL, Murray MB, Mitnick CD.

Int J Tuberc Lung Dis. 2017 Aug 1;21(8):894-901. doi: 10.5588/ijtld.16.0850.

23.

Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.

Guglielmetti L, Varaine F, Huerga H, Bonnet M, Rich ML, Mitnick CD.

Eur Respir J. 2017 Jul 20;50(1). pii: 1700598. doi: 10.1183/13993003.00598-2017. Print 2017 Jul. No abstract available.

24.

Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis.

Byrne AL, Marais BJ, Mitnick CD, Garden FL, Lecca L, Contreras C, Yauri Y, Garcia F, Marks GB.

ERJ Open Res. 2017 Jul 12;3(3). pii: 00026-2017. doi: 10.1183/23120541.00026-2017. eCollection 2017 Jul.

25.

Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.

Varaine F, Guglielmetti L, Mitnick CD.

Am J Respir Crit Care Med. 2017 Dec 1;196(11):1490-1491. doi: 10.1164/rccm.201705-0988LE. No abstract available.

PMID:
28715258
26.

Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.

Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00038-17. doi: 10.1128/AAC.00038-17. Print 2017 Aug. Erratum in: Antimicrob Agents Chemother. 2017 Aug 24;61(9):.

27.

(Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis.

Milstein M, Brzezinski A, Varaine F, Mitnick CD.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):18-23. doi: 10.5588/ijtld.16.0039. Review.

PMID:
28240568
28.

Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial.

Cellamare M, Milstein M, Ventz S, Baudin E, Trippa L, Mitnick CD.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):8-12. doi: 10.5588/ijtld.16.0066.

PMID:
28240566
29.

Optimizing MDR-TB clinical trials: insights from the first global MDR-TB Clinical Trials Landscape Meeting.

Horsburgh CR, Rusen ID, Mitnick CD.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):1-3. doi: 10.5588/ijtld.16.0568. No abstract available.

PMID:
28240564
30.

Erratum for Velásquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.

Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e00069-17. doi: 10.1128/AAC.00069-17. Print 2017 Mar. No abstract available.

31.

Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis.

Nourzad S, Jenkins HE, Milstein M, Mitnick CD.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):6-11. doi: 10.5588/ijtld.16.0110.

32.

Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective.

Kendall EA, Cohen T, Mitnick CD, Dowdy DW.

Int J Infect Dis. 2017 Mar;56:185-189. doi: 10.1016/j.ijid.2016.12.010. Epub 2016 Dec 19. Review.

33.

Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru.

Tierney DB, Milstein MB, Manjourides J, Furin JJ, Mitnick CD.

Glob Pediatr Health. 2016 Oct 26;3:2333794X16674382. eCollection 2016.

34.

Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.

Varaine F, Guglielmetti L, Huerga H, Bonnet M, Kiria N, Sitienei JK, Rich M, Mitnick CD.

Am J Respir Crit Care Med. 2016 Oct 15;194(8):1028-1029. No abstract available.

PMID:
27739887
35.

The Use of Bovine Collagen-glycosaminoglycan Matrix for Atypical Lower Extremity Ulcers.

Garwood CS, Kim PJ, Matai V, Steinberg JS, Evans KK, Mitnick CD, Attinger CE.

Wounds. 2016 Sep;28(9):298-305.

36.

Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.

Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6766-6773. doi: 10.1128/AAC.00632-16. Print 2016 Nov. Erratum in: Antimicrob Agents Chemother. 2017 Feb 23;61(3):.

37.

Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.

Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC, Burgos M, Centis R, Cohen T, Cox H, D'Ambrosio L, Danilovitz M, Falzon D, Gelmanova IY, Gler MT, Grinsdale JA, Holtz TH, Keshavjee S, Leimane V, Menzies D, Migliori GB, Milstein MB, Mishustin SP, Pagano M, Quelapio MI, Shean K, Shin SS, Tolman AW, van der Walt ML, Van Deun A, Viiklepp P; Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment.

Eur Respir J. 2016 Oct;48(4):1160-1170. doi: 10.1183/13993003.00462-2016. Epub 2016 Sep 1.

38.

Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.

Milstein M, Lecca L, Peloquin C, Mitchison D, Seung K, Pagano M, Coleman D, Osso E, Coit J, Vargas Vasquez DE, Sanchez Garavito E, Calderon R, Contreras C, Davies G, Mitnick CD.

BMC Infect Dis. 2016 Aug 27;16(1):453. doi: 10.1186/s12879-016-1790-x.

39.

A Bayesian response-adaptive trial in tuberculosis: The endTB trial.

Cellamare M, Ventz S, Baudin E, Mitnick CD, Trippa L.

Clin Trials. 2017 Feb;14(1):17-28. doi: 10.1177/1740774516665090. Epub 2016 Sep 23.

PMID:
27559021
40.

Building a Multidisciplinary Hospital-Based Wound Care Center: Nuts and Bolts.

Kim PJ, Attinger CE, Steinberg JS, Evans KK, Akbari C, Mitnick CD, Johnson-Arbor KK, Singh B.

Plast Reconstr Surg. 2016 Sep;138(3 Suppl):241S-7S. doi: 10.1097/PRS.0000000000002648.

PMID:
27556768
41.

What Heals Hidradenitis Suppurativa: Surgery, Immunosuppression, or Both?

Falola RA, DeFazio MV, Anghel EL, Mitnick CD, Attinger CE, Evans KK.

Plast Reconstr Surg. 2016 Sep;138(3 Suppl):219S-29S. doi: 10.1097/PRS.0000000000002671. Review.

PMID:
27556765
42.

Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda.

Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, Horsburgh R, Lange C, Lienhardt C, Oren E, Podewils LJ, Seaworth B, van den Hof S, Daley CL, Gebhard AC, Wares F; RESIST-TB (Research Excellence to Stop TB Resistance) and GDI (Global Drug Resistant TB Initiative).

PLoS One. 2016 May 25;11(5):e0155968. doi: 10.1371/journal.pone.0155968. eCollection 2016. Review.

43.

Presumptive treatment of multidrug-resistant tuberculosis in household contacts.

Parr JB, Rich ML, Keshavjee S, Franke MF, Mitnick CD, Bayona J, Becerra MC.

Int J Tuberc Lung Dis. 2016 Mar;20(3):370-5. doi: 10.5588/ijtld.15.0433.

PMID:
27046719
44.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P.

Int J Tuberc Lung Dis. 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490.

45.

Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis.

Fox GJ, Benedetti A, Mitnick CD, Pai M, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.

PLoS One. 2016 Mar 29;11(3):e0151724. doi: 10.1371/journal.pone.0151724. eCollection 2016.

46.

Acquired and Transmitted Multidrug Resistant Tuberculosis: The Role of Social Determinants.

Odone A, Calderon R, Becerra MC, Zhang Z, Contreras CC, Yataco R, Galea J, Lecca L, Bonds MH, Mitnick CD, Murray MB.

PLoS One. 2016 Jan 14;11(1):e0146642. doi: 10.1371/journal.pone.0146642. eCollection 2016.

47.

Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis.

Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M.

J Clin Microbiol. 2016 Mar;54(3):727-33. doi: 10.1128/JCM.02775-15. Epub 2016 Jan 13.

48.

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB, Ahuja S, Ashkin D, Avendaño M, Banerjee R, Bauer M, Burgos M, Centis R, Cobelens F, Cox H, D'Ambrosio L, de Lange WCM, DeRiemer K, Enarson D, Falzon D, Flanagan K, Flood J, Gandhi N, Garcia-Garcia L, Granich RM, Hollm-Delgado MG, Holtz TH, Hopewell P, Iseman M, Jarlsberg LG, Kim HR, Lancaster J, Lange C, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Narita M, Nathanson E, Odendaal R, O'Riordan P, Pai M, Palmero D, Park SK, Pena J, Pérez-Guzmán C, Ponce-de-Leon A, Quelapio MID, Quy HT, Riekstina V, Royce S, Salim M, Schaaf HS, Seung KJ, Shah L, Shean K, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Sung SW, Tabarsi P, Tupasi TE, Vargas MH, van Altena R, van der Walt M, van der Werf TS, Westenhouse J, Yew WW.

Clin Infect Dis. 2016 Apr 1;62(7):887-895. doi: 10.1093/cid/ciw002. Epub 2016 Jan 12.

PMID:
26757804
49.

The need to accelerate access to new drugs for multidrug-resistant tuberculosis.

Cox HS, Furin JJ, Mitnick CD, Daniels C, Cox V, Goemaere E.

Bull World Health Organ. 2015 Jul 1;93(7):491-7. doi: 10.2471/BLT.14.138925. Epub 2015 May 15.

50.

Risk factors for and origins of COPD.

Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB.

Lancet. 2015 May 2;385(9979):1723-1724. doi: 10.1016/S0140-6736(15)60884-4. No abstract available.

PMID:
25943930

Supplemental Content

Loading ...
Support Center